146 related articles for article (PubMed ID: 38798243)
21. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival.
Hegemann NS; Koepple R; Walter F; Boeckle D; Fendler WP; Angele MK; Boeck S; Belka C; Roeder F
Strahlenther Onkol; 2018 May; 194(5):435-443. PubMed ID: 29349603
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant and neoadjuvant approaches in gastric cancer.
Ng K; Meyerhardt JA; Fuchs CS
Cancer J; 2007; 13(3):168-74. PubMed ID: 17620766
[TBL] [Abstract][Full Text] [Related]
23. Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui C; Ewongwo A; Lau B; Fisher G; Delitto D; Poultsides G; Ho QA; Rahimy E; Pollom E; Chang DT; Vitzthum LK
Ann Surg Oncol; 2024 Jan; 31(1):413-420. PubMed ID: 37755563
[TBL] [Abstract][Full Text] [Related]
24. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis.
Choi M; Ishizawa S; Kraemer D; Sasson A; Feinberg E
Eur J Surg Oncol; 2022 Feb; 48(2):403-410. PubMed ID: 34446344
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature.
Franck C; Canbay A; Malfertheiner P; Venerito M
Mol Clin Oncol; 2017 Dec; 7(6):1069-1072. PubMed ID: 29285376
[TBL] [Abstract][Full Text] [Related]
26. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
Kim HD; Lee JS; Park YS; Yook JH; Noh SH; Park YK; Kim YW; Oh SC; Kim JG; Ryu MH; Cheong JH; Kim H; Lim JS; Lee JH; Heo SH; Kim JY; Heo MH; Park YI; Kim IH; Kang YK
Gastric Cancer; 2022 Nov; 25(6):1039-1049. PubMed ID: 35920999
[TBL] [Abstract][Full Text] [Related]
27. Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study.
Skubleny D; Lin A; Garg S; McLean R; McCall M; Ghosh S; Spratlin JL; Schiller D; Rayat G
World J Gastrointest Oncol; 2023 Feb; 15(2):303-317. PubMed ID: 36908322
[TBL] [Abstract][Full Text] [Related]
28. Multidisciplinary management of gastric and gastroesophageal cancers.
Moehler M; Lyros O; Gockel I; Galle PR; Lang H
World J Gastroenterol; 2008 Jun; 14(24):3773-80. PubMed ID: 18609699
[TBL] [Abstract][Full Text] [Related]
29. Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancers-Analysis from a Large Single Center Cohort in Germany.
Schirren R; Novotny A; Friess H; Reim D
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796715
[TBL] [Abstract][Full Text] [Related]
30. Perioperative therapy for esophageal cancer.
Yamasaki M; Miyata H; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Gen Thorac Cardiovasc Surg; 2014 Sep; 62(9):531-40. PubMed ID: 25065567
[TBL] [Abstract][Full Text] [Related]
31. [Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers].
Stocker G; Thieme R; Lordick F
Chirurg; 2021 Jun; 92(6):499-505. PubMed ID: 33566116
[TBL] [Abstract][Full Text] [Related]
32. The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Wang X; Li S; Sun Y; Li K; Shen X; Xue Y; Liang P; Li G; Chen L; Zhao Q; Li G; Fu W; Liang H; Xin H; Suo J; Fang X; Zheng Z; Xu Z; Chen H; Zhou Y; He Y; Huang H; Zhu L; Yang K; Ji J; Ye Y; Zhang Z; Li F; Wang X; Tian Y; Park S; Chen L
BMC Cancer; 2021 Jan; 21(1):20. PubMed ID: 33402102
[TBL] [Abstract][Full Text] [Related]
33. [Gastric and pancreatic cancers: Will neoadjuvant (chemo)radiotherapy replace adjuvant chemoradiotherapy?].
Huguet F; Rivin Del Campo E; Labidi M; Ménard J; Sergent G; Durand B; Quéro L
Cancer Radiother; 2020 Oct; 24(6-7):493-500. PubMed ID: 32814670
[TBL] [Abstract][Full Text] [Related]
34. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
[TBL] [Abstract][Full Text] [Related]
35. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT.
Geerts JFM; van der Zijden CJ; van der Sluis PC; Spaander MCW; Nieuwenhuijzen GAP; Rosman C; van Laarhoven HWM; Verhoeven RHA; Wijnhoven BPL; Lagarde SM; Mostert B
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610969
[No Abstract] [Full Text] [Related]
36. A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer.
Anderson E; LeVee A; Kim S; Atkins K; Guan M; Placencio-Hickok V; Moshayedi N; Hendifar A; Osipov A; Gangi A; Burch M; Waters K; Cho M; Klempner S; Chao J; Kamrava M; Gong J
JAMA Netw Open; 2021 Dec; 4(12):e2138432. PubMed ID: 34889947
[TBL] [Abstract][Full Text] [Related]
37. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis.
van den Ende T; Ter Veer E; Machiels M; Mali RMA; Abe Nijenhuis FA; de Waal L; Laarman M; Gisbertz SS; Hulshof MCCM; van Oijen MGH; van Laarhoven HWM
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30641964
[No Abstract] [Full Text] [Related]
38. Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence.
Nakauchi M; Vos E; Tang LH; Gonen M; Janjigian YY; Ku GY; Ilson DH; Maron SB; Yoon SS; Brennan MF; Coit DG; Strong VE
Ann Surg Oncol; 2021 Sep; 28(9):4829-4838. PubMed ID: 33566242
[TBL] [Abstract][Full Text] [Related]
39. Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives.
Tokunaga M; Sato Y; Nakagawa M; Aburatani T; Matsuyama T; Nakajima Y; Kinugasa Y
Surg Today; 2020 Jan; 50(1):30-37. PubMed ID: 31612329
[TBL] [Abstract][Full Text] [Related]
40. Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy.
Gao X; Zhang Y; Yuan F; Ding B; Ma Q; Yang W; Yan J; Du L; Wang B; Yan F; Sedlmair M; Pan Z; Zhang H
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2207-2218. PubMed ID: 30094537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
